Showing results (1181-1190 of 1,824) with videos related to

Sort By:
Pageof 183
Journal of Experimental Botany|December 31, 2016
Related to ABI3/VP1-Like 1 (RAVL1) regulates brassinosteroid-mediated activation of AMT1;2 in rice (Oryza sativa)Yuan Hu Xuan, Feng Ying Duan, Byoung Il Je, et al.
Bone Marrow Transplantation|May 30, 2003
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)Nicolaus Kröger, Hermann Einsele, Daniel Wolff, et al.
International Journal of Colorectal Disease|March 3, 2006
Prevalence of the mismatch-repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year follow-up study, Annegret Müller, Carmen Beckmann, et al.
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
Journal of Hematology & Oncology|March 17, 2018
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMTAnnalisa Ruggeri, Myriam Labopin, Andrea Bacigalupo, et al.
Leukemia Research|May 25, 2015
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Myriam Labopin, Ali Bazarbachi, et al.
Cancer Research|February 19, 2009
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapyJohannes H Schulte, Soyoung Lim, Alexander Schramm, et al.
Clinical & Developmental Immunology|December 23, 2011
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantationSebastian Kobold, Sinje Tams, Tim Luetkens, et al.
Blood Advances|January 20, 2022
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosisNico Gagelmann, Christine Wolschke, Rachel B Salit, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 24, 2015
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?Aleksandar Radujkovic, Cesare Guglielmi, Stefania Bergantini, et al.
Pageof 183